Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation

Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation

Non-alcoholic fatty liver disease (NAFLD) is becoming an epidemic disease in adults and children worldwide. Importantly, there are currently no approved treatments available for NAFLD. This study aims to investigate the potential applications of sodium tanshinone IIA sulfonate (STS) on improving the...

Full description

Bibliographic Details
Main Authors: Xiao-Xiao Li, Xin-Yi Lu, Shi-Jie Zhang, Amy P. Chiu, Lilian H. Lo, David A. Largaespada, Qu-Bo Chen, Vincent W. Keng
Format: Article
Language:English
Published: Elsevier 2019-03-01
Series:Biomedicine & Pharmacotherapy
Subjects:
NAFLD
Sodium tanshinone IIA sulfonate
SIRT1
PRKAA1
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332218376376

Internet

http://www.sciencedirect.com/science/article/pii/S0753332218376376

Similar Items